



MAUNA KEA TECHNOLOGIES ANNOUNCES RESULTS OF ITS ANNUAL SHAREHOLDERS MEETING

PARIS, (May 29, 2015) - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the results of its Annual Meeting of Shareholders, which was held on May 27th, 2015 in Paris under the chairmanship of Sacha Loiseau, General Manager and board member and with a quorum of 45% of the shares.

All resolutions supported by management were approved except the 11th resolution.

Shareholders approved the company's consolidated financial statements for the year ended December 31, 2014.

For additional details, Mauna Kea Technologies invites its shareholders to refer to the minutes of the Annual Shareholders Meeting, available on investor section of the company's website (in French)

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy and optical biopsy. The company designs, develops and markets innovative tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. The company's flagship product, Cellvizio®, a probe needlebased Confocal Laser Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with high-resolution cellular imaging of internal tissues. Large-scale, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early forms of diseases and make immediate treatment decisions. Designed to help physicians in their diagnoses, provide patients with better treatment and reduce hospital costs, the Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k) clearance from the United States Food and Drug Administration and CE Marking in the European Union for use in the gastrointestinal tract and the urinary and respiratory systems, for endoscopic exploration of the biliary and pancreatic ducts and for fine-needle aspiration procedures. Cellvizio has also obtained SFDA regulatory approval in China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

NewCap.

Investor Relations Europe
Florent Alba
Tel: +33 (0) 1 44 71 94 94
maunakea@newcap.fr